Skip to content

Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate

Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate: An Efficacy and Safety Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121515
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic spasm and colorectal polyps

Interventions

Experimental group:Endoscopic irrigation with 0.1% menthol solution combined with dimethyl silicone oil suspension
Control group:Endoscopic irrigation with a water suspension prepared from dimethyl silicone oil and normal saline

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18–75 years, both sexes/gender not limited. 2. Planned for colonoscopy (for screening, diagnostic, or follow-up purposes); 3. Adequate bowel preparation quality (Boston Bowel Preparation Scale score >= 6); 4. Voluntarily signed informed consent and is able to cooperate in completing study-related assessments.

Exclusion criteria

Exclusion criteria: 1. Allergic to menthol, cyclodextrin, or related substances; 2. History of severe intestinal diseases (such as ulcerative colitis, Crohn’s disease, intestinal perforation, intestinal obstruction, intestinal tumors, etc.); 3. With combined severe dysfunction of major organs such as the heart, liver, kidneys, or lungs, or coagulation disorders. 4. Pregnant or lactating women; 5. Those who have used anticholinergic drugs, calcium channel blockers, or other antispasmodic medications within one week prior to the examination. 6. Individuals with mental illness or cognitive impairment that prevents them from cooperating with the study. 7. Those with a history of contraindications to colonoscopy or serious adverse reactions.

Design outcomes

Primary

MeasureTime frame
Incidence of intestinal spasm;Adenoma detection rate;

Secondary

MeasureTime frame
Spasm inhibition rate;Polyp detection rate;Time of cecal intubation;Withdrawal time;Usage rate of intravenous antispasmodics;

Countries

China

Contacts

Public ContactJianning Yao

The First Affiliated Hospital of Zhengzhou University

Jianningyao@163.com+86 371 6627 1117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026